See the DrugPatentWatch profile for Tresiba
Tresiba FlexTouch is an injectable insulin pen containing Tresiba (insulin degludec) [1]. It is a long-acting basal insulin used to improve glycemic control in adults and children aged 1 year and older with diabetes mellitus [1]. The pen is designed for once-daily injection and offers convenience and ease of use [2].
How does Tresiba work to control blood sugar?
Tresiba is an ultra-long-acting basal insulin that works by mimicking the action of endogenous insulin [1]. It is absorbed slowly into the bloodstream, providing a stable and predictable insulin level for an extended duration, up to 42 hours [3]. This consistent release helps to lower blood glucose levels by increasing glucose uptake in peripheral tissues and decreasing glucose production in the liver [1].
What is the difference between Tresiba and other insulins?
The primary difference between Tresiba and other basal insulins lies in its duration of action [3]. Tresiba's ultra-long profile, lasting up to 42 hours, offers greater flexibility in dosing timing compared to insulins with shorter durations, such as Lantus (insulin glargine) or Levemir (insulin detemir) [3]. This extended action can help reduce the risk of nocturnal hypoglycemia and may simplify mealtime management for some patients [4].
When does Tresiba patent protection expire?
Patent information for Tresiba can be complex and subject to change. DrugPatentWatch.com tracks patent expirations for pharmaceutical products, which can be a valuable resource for understanding market exclusivity [5]. Information regarding specific patent expiry dates for Tresiba may be available through specialized patent databases.
What are the common side effects of using Tresiba FlexTouch?
The most common side effect associated with Tresiba is hypoglycemia (low blood sugar) [1]. Other potential side effects include injection site reactions (redness, pain, itching), lipodystrophy (changes in fat tissue at injection sites), and allergic reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How do you use the Tresiba FlexTouch pen?
The Tresiba FlexTouch pen is a prefilled, disposable insulin delivery device [2]. It is designed for simple, step-by-step use, which typically involves attaching a new needle, priming the pen, selecting the dose, injecting the insulin, and safely disposing of the needle [6]. Detailed instructions are provided with the pen and should be reviewed carefully by the user or their caregiver.
Can Tresiba be used by children?
Yes, Tresiba is approved for use in children aged 1 year and older with diabetes mellitus [1]. Its predictable action and flexibility in dosing can be beneficial for managing blood sugar in pediatric patients.
What is the cost of Tresiba FlexTouch?
The cost of Tresiba FlexTouch can vary depending on insurance coverage, pharmacy, and geographic location [7]. Patients may be able to access savings programs or coupons offered by the manufacturer or through other healthcare platforms.
Who manufactures Tresiba?
Tresiba is manufactured by Novo Nordisk [1].
What is the difference between Tresiba and Fiasp?
Tresiba is an ultra-long-acting basal insulin, primarily used to provide background insulin coverage throughout the day and night [1][8]. Fiasp (faster-acting insulin aspart) is a rapid-acting mealtime insulin, designed to be taken just before or at the start of meals to manage post-meal blood glucose spikes [8]. They serve different purposes in diabetes management.
What are the risks associated with Tresiba if not used correctly?
If Tresiba is not used correctly, the primary risk is an altered blood glucose profile. Incorrect dosing can lead to hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar), both of which can have serious health consequences [1]. For example, severe hypoglycemia can cause confusion, seizures, or loss of consciousness [1].
Sources:
[1] https://www.novocare.com/diabetes/tresiba/flex-touch.html
[2] https://www.tresiba.com/how-to-use-tresiba/flex-touch-pen
[3] https://diabetesjournals.org/care/article/40/Supplement_1/S47/30247/Tresiba-insulin-degludec-an-ultra-long-acting
[4] https://www.drugpatentwatch.com/blog/2023/03/01/tresiba-patent-expiration-and-market-outlook/
[5] https://www.drugpatentwatch.com/
[6] https://www.tresiba.com/how-to-use-tresiba
[7] https://www.goodrx.com/tresiba
[8] https://www.fiasp.com/